Targeting RANK/RANKL in the treatment of solid tumours and myeloma

Area of Science:

• Oncology
• Bone Biology
• Metastasis

Background:

• Cancers like multiple myeloma, breast, and prostate cancer can metastasize to bone, directly colonizing bone or forming outgrowths.
• Tumor cells interact with the bone microenvironment, affecting bone formation and resorption, leading to clinical issues like bone pain and fractures.
• The RANK/RANKL/OPG pathway is crucial for normal bone remodeling and is implicated in the osteolytic and osteoblastic lesions characteristic of cancer metastasis to bone.

Purpose of the Study:

• To investigate the role of the RANK/RANKL/OPG pathway in bone diseases associated with skeletal cancers.
• To explore therapeutic strategies targeting the RANK/RANKL/OPG system for treating bone metastases.

Main Methods:

• Review of pre-clinical studies focusing on targeting the RANK/RANKL/OPG pathway.
• Analysis of therapeutic agents including OPG constructs, peptidomimetics, soluble receptor constructs, and RANKL antibodies.

Main Results:

• The RANK/RANKL/OPG system is identified as a key effector pathway in skeletal cancers.
• Pre-clinical studies targeting this pathway have shown success, indicating therapeutic potential.
• Successful pre-clinical research has led to clinical programs for novel treatments.

Conclusions:

• The RANK/RANKL/OPG pathway is a critical target for managing bone complications in skeletal cancers.
• Targeting this pathway represents a promising new therapeutic approach for cancers that metastasize to the skeleton.